August 01, 2012 07:30 ET

International Law Firm Winston & Strawn Retained as Counsel for Immunovative, Inc.

NOTE TO EDITORS: The Following Is an Investment Opinion Being Issued by the OTC REPORT

NEW YORK, NY--(Marketwire - Aug 1, 2012) - The following is an investment opinion on Vical Inc (NASDAQ: VICL), Celldex Therapeutics, Inc. (NASDAQ: CLDX), NewLink Genetics (NASDAQ: NLNK) and Immunovative, Inc. (OTCBB: IMUN). Immunovative, Inc. (OTCBB: IMUN) an exclusive worldwide licensee of Israeli biopharmaceutical company Immunovative Therapies, Ltd., announced today that they have retained Winston & Strawn LLP, as their legal counsel. Winston & Strawn have nearly 1,000 employees over 15 offices across the world.

In December 2011, Immunovative, Inc. signed an exclusive worldwide license agreement with Immunovative Therapies, Ltd. to commercialize any products currently issued or to be issued in the future by Immunovative Therapies. Immunovative Therapies, Ltd. is an Israeli biopharmaceutical company that was founded in May 2004 with financial support from the Israel Office of the Chief Scientist. Immunovative is a graduate of the Misgav Venture Accelerator, a member of the world-renowned Israel technological incubator program.

Immunovative focuses on developing and commercializing innovative cancer treatments by harnessing the power of the immune system. According to the American Cancer Society, "Immunotherapy is a very active area of cancer research. Many scientists and doctors around the world are studying new ways to use immunotherapy to treat cancer." Companies like Immunovative that are focused on immunotherapy are Vical Inc (NASDAQ: VICL), Celldex Therapeutics, Inc. (NASDAQ: CLDX) and NewLink Genetics (NASDAQ: NLNK).

For more information, please visit

This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Information, opinions and analysis contained herein are based on sources deemed to be reliable and are subject to change without notice. A third party has hired and paid OTC Report one thousand two hundred and ninety five dollars for the publication and circulation of this news release. Accordingly, certain information included herein may be forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. However, no representation, expressed or implied, is made as to the accuracy, completeness or correctness. In light of the above, we accept no liability for any losses arising from an investor's reliance on or use of this report. We do not and have not had any ownership interest in said third party of any kind.

Contact Information